Litigators of the Week Runners-Up and Shout Outs — Avadel Pharmaceuticals and The Trade Desk
Latham lawyers were honored for securing big victories for Avadel Pharmaceuticals and The Trade Desk.
Thomas (Tom) Giblin advises companies and individuals on a full range of civil and regulatory matters, including securities litigation, M&A-related litigation, shareholder derivative litigation, and government investigations.
Tom helps clients navigate the complex litigation and regulatory landscape that securities issuers, corporate directors and officers, auditors, and financial institutions face. He has decades of experience representing clients in federal securities class actions, merger-related disputes, and investigations by regulators in the US and abroad, including the Department of Justice (DOJ), Securities Exchange Commission (SEC), and Commodity Futures Trading Commission (CFTC).
Tom draws on a background in economics and a keen understanding of the underlying business needs of his clients. He frequently secures dismissal of securities litigation at the pleading stage and regularly resolves matters before they proceed to trial.
Tom maintains an active pro bono practice. In one notable matter, he won a favorable verdict at trial for a small business owner accused of violating federal and state labor laws, and successfully argued for affirmance by the Second Circuit Court of Appeals.
During law school, he served on the editorial board of the Columbia Business Law Review. Tom has clerked for the Honorable Gary L. Lancaster, Chief Judge of the United States District Court for the Western District of Pennsylvania, as well as the Honorable Thomas P. Agresti, Chief Judge of the United States Bankruptcy Court for the Western District of Pennsylvania.
Tom’s experience includes representing:
Latham lawyers were honored for securing big victories for Avadel Pharmaceuticals and The Trade Desk.
Latham lawyers honored for securing the dismissal of a securities fraud complaint brought against Funko and its former CEO and CFO, and for a win at the D.C. Circuit for United Therapeutics.
New York Securities Litigation team recognized for outstanding results, particularly at trial, in the past year.